By Ethan Covey
Patients with recent Pseudomonas aeruginosa infection or colonization are at higher risk for community-acquired pneumonia (CAP), and may benefit from empiric antipseudomonal therapy for CAP, according to a study presented during the IDWeek 2021 virtual conference.
“The 2019 American Thoracic Society/IDSA [Infectious Diseases Society of America] CAP guidelines recommend empiric PSA coverage if locally validated risk factors are present,” said Emily A. Gibbons,